SAN DIEGO--Structural Bioinformatics (SBI) here and BioChem Therapeutics, a wholly owned subsidiary of Biochem Pharma, Laval, Quebec, have agreed to collaborate on drug discovery and design using SBI's proprietary computational technologies. SBI will apply its genomics-driven, protein-structure-based drug design algorithms to facilitate the design and identification of small molecules for two targets selected by BioChem. BioChem will contribute drug development expertise, fund the research, and make milestone and royalty payments.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.